Literature DB >> 1639853

Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1.

B A Arrick1, A R Lopez, F Elfman, R Ebner, C H Damsky, R Derynck.   

Abstract

Transforming growth factor-beta (TGF-beta) is a potent mediator of cell proliferation and extracellular matrix formation, depending on the cell type and the physiological conditions. TGF-beta is usually secreted in a "latent" complex that needs activation before it can exert its effects. Several observations correlate increased expression of TGF-beta 1 with tumorigenesis. To evaluate the physiological relevance of increased TGF-beta 1 synthesis in tumor cells we established cell clones overexpressing TGF-beta 1 and observed the resulting physiological changes in TGF-beta overproducing cells in vitro and in vivo. As a model system we used the human E1A-transformed 293 tumor cells, which are insensitive to the direct growth modulatory effects of TGF-beta. The selection of this cell line allows an assessment of physiological alterations independent of TGF-beta induced proliferative changes. The use of two TGF-beta 1 expression vectors containing either the natural or a modified TGF-beta 1 precursor cDNA permitted the establishment of separate 293 cell lines overexpressing latent or active TGF-beta. Comparison of the resulting changes in glycolytic rate, adhesiveness and integrin and plasminogen activator expression established that, in vitro, both types of clones behaved similarly, indicating that expression of latent TGF-beta induces autocrine changes in the tumor cells and thus suggesting that some level of cell-associated activation occurs. TGF-beta overexpression resulted in an increased metabolic rate due to enhanced glycolysis, a property long associated with tumor cells. This increased glycolysis was not associated with altered proliferation. Cells overexpressing TGF-beta also displayed enhanced fibronectin mRNA and plasminogen activator synthesis and increased adhesiveness in vitro. They showed enhanced survival when plated sparsely on plastic in the absence of serum, and attached more readily to laminin. In addition, synthesis of several beta 1 integrins, in particular the alpha 1/beta 1, alpha 2/beta 1, and alpha 3/beta 1, all of which recognize laminin, were enhanced. Finally, cells overexpressing active TGF-beta, but not latent TGF-beta, also showed increased tumorigenicity in nude mice. Thus, an increase in endogenous TGF-beta synthesis confers several proliferation-independent phenotypic changes which may be of significance for the survival of the tumor cell inoculum or its subsequent growth, and for tumor formation and development. In the case of cells expressing active TGF-beta, the release of active TGF-beta into the vicinity of the tumor cells may also result in a more hospitable environment for tumor growth.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1639853      PMCID: PMC2289543          DOI: 10.1083/jcb.118.3.715

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  50 in total

1.  Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia.

Authors:  D B Constam; J Philipp; U V Malipiero; P ten Dijke; M Schachner; A Fontana
Journal:  J Immunol       Date:  1992-03-01       Impact factor: 5.422

2.  Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma.

Authors:  N Ito; S Kawata; S Tamura; K Takaishi; Y Shirai; S Kiso; I Yabuuchi; Y Matsuda; M Nishioka; S Tarui
Journal:  Cancer Res       Date:  1991-08-01       Impact factor: 12.701

3.  Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor.

Authors:  P A Dennis; D B Rifkin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

4.  Loss of growth control by TGF-beta occurs at a late stage of mouse skin carcinogenesis and is independent of ras gene activation.

Authors:  S Haddow; D J Fowlis; K Parkinson; R J Akhurst; A Balmain
Journal:  Oncogene       Date:  1991-08       Impact factor: 9.867

5.  Glycoproteins of 210,000 and 130,000 m.w. on activated T cells: cell distribution and antigenic relation to components on resting cells and T cell lines.

Authors:  M E Hemler; F Sanchez-Madrid; T J Flotte; A M Krensky; S J Burakoff; A K Bhan; T A Springer; J L Strominger
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

6.  Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel.

Authors:  R Fridman; M C Kibbey; L S Royce; M Zain; M Sweeney; D L Jicha; J R Yannelli; G R Martin; H K Kleinman
Journal:  J Natl Cancer Inst       Date:  1991-06-05       Impact factor: 13.506

7.  Distribution patterns of extracellular matrix components and adhesion receptors are intricately modulated during first trimester cytotrophoblast differentiation along the invasive pathway, in vivo.

Authors:  C H Damsky; M L Fitzgerald; S J Fisher
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

8.  TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis.

Authors:  M T Jennings; R J Maciunas; R Carver; C C Bascom; P Juneau; K Misulis; H L Moses
Journal:  Int J Cancer       Date:  1991-08-19       Impact factor: 7.396

9.  Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro.

Authors:  M S Steiner; E R Barrack
Journal:  Mol Endocrinol       Date:  1992-01

10.  TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector.

Authors:  S P Wu; D Theodorescu; R S Kerbel; J K Willson; K M Mulder; L E Humphrey; M G Brattain
Journal:  J Cell Biol       Date:  1992-01       Impact factor: 10.539

View more
  32 in total

1.  Neurons promote macrophage proliferation by producing transforming growth factor-beta2.

Authors:  A Dobbertin; P Schmid; M Gelman; J Glowinski; M Mallat
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

2.  Restoration of Smad4 in BxPC3 pancreatic cancer cells attenuates proliferation without altering angiogenesis.

Authors:  Michiya Yasutome; Jason Gunn; Murray Korc
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Transforming growth factor beta as a potential tumor progression factor among hyperdiploid glioblastoma cultures: evidence for the role of platelet-derived growth factor.

Authors:  M T Jennings; C E Hart; P A Commers; J A Whitlock; D Martincic; R J Maciunas; P L Moots; T M Shehab
Journal:  J Neurooncol       Date:  1997-02       Impact factor: 4.130

4.  TGF beta-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein.

Authors:  R E Herrera; T P Mäkelä; R A Weinberg
Journal:  Mol Biol Cell       Date:  1996-09       Impact factor: 4.138

5.  Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta.

Authors:  A Hildebrand; M Romarís; L M Rasmussen; D Heinegård; D R Twardzik; W A Border; E Ruoslahti
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

6.  Influence of TGFB1 C-509T polymorphism on gastric cancer risk associated with TGF-β1 expression in the gastric mucosa.

Authors:  Yoon Jin Choi; Nayoung Kim; Aesun Shin; Hye Seung Lee; Ryoung Hee Nam; Hyun Chang; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Ji Hyun Park; Hyun Chae Jung
Journal:  Gastric Cancer       Date:  2014-08-14       Impact factor: 7.370

7.  T-Cell type acute lymphoblastic leukemia following cyclosporin A therapy for aplastic anemia.

Authors:  Y Hirose; Y Masaki; K Ebata; J Okada; C G Kim; N Ogawa; Y Wano; S Sugai
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

8.  Mammary tumor suppression by transforming growth factor beta 1 transgene expression.

Authors:  D F Pierce; A E Gorska; A Chytil; K S Meise; D L Page; R J Coffey; H L Moses
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

9.  Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma.

Authors:  B I Dalal; P A Keown; A H Greenberg
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

10.  Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.

Authors:  C L Arteaga; S D Hurd; A R Winnier; M D Johnson; B M Fendly; J T Forbes
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.